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Purinergic modulation of mesangial extracellular matrix pro-
duction: Role in diabetic and other glomerular diseases.
Background. Extracellular adenosine triphosphate (ATP)
(eATP) mediates several biologic activities via purinergic P2
receptors (P2Rs). This study aimed at (1) evaluating the role
of the purinergic system in modulating mesangial extracellular
matrix (ECM) and transforming growth factor-b (TGF-b) pro-
duction and (2) its contribution to diabetes-induced mesangial
ECM accumulation.
Methods. Rat mesangial cells were grown in normal glucose
(5.5 mmol/L) or high glucose (30 mmol/L) containing media and
probed with purinergic agonists and antagonists for the assess-
ment of the expression pattern and function of P2Rs; release
of ATP and activity of ectoATPases; and changes in ECM and
TGF-b expression.
Results. Cells cultured in normal glucose and high glucose ex-
pressed similar amounts of functional P2Rs of the P2X2, P2X3,
P2X4, P2X5, P2X7, P2Y1, P2Y2, P2Y4, and P2Y6 subtypes. Lev-
els of eATP were higher in high glucose vs. normal glucose, with
unchanged ectoATPase activity. The ATP-hydrolyzing enzymes
hexokinase or apyrase reduced ECM and TGF-b production
from cells grown in high glucose, but not normal glucose. Under
both normal glucose and high glucose conditions, ATP and the
P2X7 agonist benzoylbenzoylATP increased dose-dependently
ECM and TGF-b production, whereas the P2Y agonist uridine
triphosphate produced the opposite effect. The P2X7 inhibitor
oxidized ATP attenuated the ECM and TGF-b up-regulation
induced by ATP and, to a lesser extent, that caused by high
glucose. A TGF-b neutralizing antibody also prevented ATP-
induced ECM up-regulation.
Conclusion. These data indicate a role for eATP in regulating
ECM production via TGF-b and suggest that P2XRs and P2YRs
differentially modulate this process. An increased ATP release
induced by hyperglycemia might contribute to mesangial matrix
expansion occurring in diabetes.
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Purinergic nucleotides and receptors represent an au-
tocrine/paracrine system that participates in the regula-
tion of cell function. Release of adenosine triphosphate
(ATP) from the cell can occur by conductive trans-
port, facilitated transport, and exocytosis. In the ex-
tracellular space, ATP is degraded by ectoenzymes
such as ectonucleotide triphosphate diphosphohydro-
lases [that degrade both ATP and adenosine diphos-
phate (ADP) to adenosine monophosphate (AMP)
and inorganic phosphate], ectonucleotide pyrophos-
phatases/phosphodiesterases (that degrade ATP to AMP
and pyrophosphate) or alkaline phosphatase. AMP is
then hydrolyzed by 5′-nucleotidase to generate adeno-
sine [1]. ATP and ADP bind to G protein–coupled
purinergic P2Y receptors (P2YRs), with consequent acti-
vation of phospholipase C-b , generation of diacylglycerol
and inositol-3-phosphate, activation of protein kinase C
(PKC), and release of calcium from intracellular stores
[2, 3]. ATP also binds to and activates purinergic P2X re-
ceptors (P2XRs), thus causing transmembrane calcium,
sodium and potassium fluxes, with consequent membrane
depolarization that may drive further calcium influx [2,
3]. AMP and adenosine interact with purinergic P1 recep-
tors, with effects depending on the receptor subtype(s)
[4]. While it was long believed that extracellular ATP
(eATP) levels were basically negligible, it is now clear
that presence of eATP in the pericellular space is the
rule rather than the exception in several physiologic
and pathologic conditions [1], thus leading to differen-
tial modulation of P2R activity even in the absence of
added ATP [5].
It has been shown that P2YRs and P2XRs are ex-
pressed along the nephron and renal vasculature [1, 6]
and that ATP is released by renal tubular epithelial cells
[7], endothelial cells [8], smooth muscle cells [8], platelets
[8], and nerves (as a cotransmitter of norepinephrine)
[9], thus suggesting that the purinergic system exerts sev-
eral physiologic functions at the kidney level by acting in
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an autocrine/paracrine manner. The data available so far
show that this system regulates renal microvascular func-
tion, glomerular capillary pressure and tubuloglomeru-
lar feedback [10, 11]. It is also involved in the control
of glomerular volume through at least two mechanisms:
an ATP-dependent glomerular relaxation, mediated by
P2YRs possibly at the endothelial level, and a subsequent
contraction, caused by either ATP itself (acting on mesan-
gial cells or podocytes) or adenosine formed by ATP hy-
drolysis [12]. P2X7 as well as P2Y2, P2Y4 and P2Y6 were
found to be expressed in rat mesangial cells [13, 14] and to
exert opposite effects on cell turnover. The P2YRs (likely
P2Y2 and P2Y4) were shown to promote mesangial cell
proliferation [13, 15], via activation of mitogen-activated
protein kinase (MAPK) [16] and induction of immediate
early genes [17]. Conversely, P2X7 was shown to induce
mesangial cell death by apoptosis and necrosis [13, 18].
Together with altered glomerular cell turnover,
abnormal extracellular matrix (ECM) deposition, result-
ing from an imbalance between synthesis and degrada-
tion, represents the main process underlying virtually all
forms of renal disease, including diabetic nephropathy
[19]. Mesangial cells make a major contribution to this
sclerosing process, by producing increased amounts of
matrix proteins in response to hyperglycemia [20], and
transforming growth factor-b (TGF-b) is considered the
main cytokine modulating ECM accumulation, since it
promotes matrix synthesis and reduces its degradation
[21].
This study using rat mesangial cells grown under nor-
mal glucose and high glucose conditions was aimed at
evaluating (1) the role of the purinergic system in mod-
ulating mesangial ECM and TGF-b production and (2)
its contribution to the accumulation of matrix proteins
within the mesangium in diabetes.
METHODS
Design
Rat mesangial cells were cultured in media containing
normal glucose (5.5 mmol/L) or high glucose (30 mmol/L)
concentrations and probed with various purinergic
agonists and antagonists. These agents included (1)
the enzymes degrading endogenous ATP, hexokinase
(50 lg/mL), and apyrase (4 U/mL), added for 4 hours; (2)
the P2R agonists ATP, benzoylbenzoylATP (Bz-ATP),
uridine triphosphate (UTP), and 2-methylthioadenosine-
5′-triphosphate (2-MeS-ATP) at increasing doses (0.001,
0.01, 0.05, 0.15, 0.30, 0.50, and 1 mmol/L) for 4 hours; (3)
the P2R antagonists pyridoxalphosphate-6-azophenyl-
2′,4′,-disulfonic acid (PPADS), oxidized ATP (oATP) and
2′-deoxy-N6-methyladenosine 3′,5′-bisphosphate (MRS-
2179), given for 2 hours at the dosage of 0.30 mmol/L
either alone or followed by coincubation with equimolar
ATP for further 4 hours; and (4) a TGF-b blocking an-
tibody or control chicken IgG, added for 4 hours at the
concentration of 30 lg/mL together with 0.30 mmol/L
ATP. All these experiment had a control for osmolarity
[i.e., media containing iso-osmolar mannitol concentra-
tions (5.5 mmol/L glucose + 24.5 mmol/L mannitol)]. All
reagents were purchased from Sigma Chemical Co. (St.
Louis, MO, USA), except for MRS-2179, obtained from
Tocris Cookson Ltd. (Bristol, UK), and TGF-b blocking
antibody and control chicken IgG, purchased from R&D
Systems (Minneapolis, MN, USA).
Under these experimental conditions, the following
parameters were assessed: (1) expression pattern and
function of purinergic receptors; (2) release of ATP and
activity of ecto-ATPases; and (3) changes in ECM and
TGF-b mRNA and protein expression in response to
purinergic agonists and antagonists.
Cell culture
Rat mesangial cells were isolated and characterized
as previously described [22]. For the experimental pro-
cedures, rat mesangial cells between the third and the
tenth passage were cultured for 10 to 15 days (over
two to three passages) in Dulbecco’s modified Eagle’s
medium (Sigma Chemical Co.) supplemented with 17%
fetal bovine serum, 2 mmol/L L-glutamine, and antibi-
otics, at 37◦C in 95% air-5% CO2 humidified atmosphere
[28], under the glucose concentrations indicated above.
Expression and functional activity of purinergic receptors
P2YR and P2XR mRNA levels were measured by
reverse transcription-polymerase chain reaction (RT-
PCR) from total RNA extracts obtained by the acid
guanidinium thiocianate-phenol-chloroform method us-
ing TRIzol Reagent (Invitrogen Italia SRL, San Giu-
liano Milanese, Italy). Total RNA was reverse transcribed
and resulting cDNA was amplified using Access RT-PCR
System (Promega, Madison, WI, USA). Amplification
primers for P2YR and P2XR subtypes and the house-
keeping gene b-actin were the following: P2Y1 sense 5′-
CAT CTC CCC CAT TCT CTT-3′ and antisense 5′-GTT
GCT TCT TCT TGA CCT GT-3′; P2Y2 sense 5′-ACC
CGC ACC CTC TAT TAC T-3′ and antisense 5′-CTT
AGA TAC GAT TCC CCA ACT-3′; P2Y4 sense 5′-TGG
GTG TTT GGT TGG TAG TA-3′ and antisense 5′-GTC
CCC CGT GAA GAG ATA G-3′; P2Y6 sense 5′-GTT
ATG GAG CGG GAC AAT GG-3′ and antisense 5′-
AGG ATG CTG CCG TGT AGG TT-3′; P2X1 sense 5′-
CAT TGT GCA GAG AAC CCA GAA-3′ and antisense
5′-ATG TCC TCC GCA TAC TTG AAC-3′; P2X2 sense
5′-GTT CAC AGC TCT ACC TGC-3′ and antisense 5′-
GAT GAC TCC AAT GAC ACC-3′; P2X3 sense 5′-TTC
TTC ACC TAC GAG ACT ACC-3′ and antisense 5′-TTA
ACC ACA TCC CCT ACC-3′; P2X4 sense 5′-AGG GCT
ACC AGG AAA CGG AC-3′ and antisense 5′-GAT
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TGT GCC AAG ACG GAA TA-3′; P2X5 sense 5′-ATC
TCT ACT GTC CCA TCT TCC-3′ and antisense 5′-TTG
CTA TTC TGC TTC CTC C-3′; P2X6 sense 5′-TAA CCA
ACT TCC TTG TGA CAC C-3′ and antisense 5′-TGA
AAT TGT ACC CCC TCT CC-3′; P2X7 sense 5′-AGG
AGC CCC TTA TCA GCT CT-3′ and antisense 5′-CAT
TGG TGT ACT TGT CGT CC-3′; and b-actin sense 5′-
TGG GAA TGG GTC AGA AGG ACT-3′ and antisense
5′-TTT CAC GGT TGG CCT TAG GGT-3′. Oligonu-
cleotides were synthesized by M-Medical Genenco-Life
Science (Florence, Italy). Amplification products were
separated in 2% agarose gels, stained with ethidium bro-
mide and quantified by scanning densitometry.
For P2X7, protein expression was verified by West-
ern blot analysis. Cells were lysed in lysis buffer
[300 mmol/L sucrose, 1 mmol/L K2HPO4, 1 mmol/L
MgSO4, 5.5 mmol/L glucose, 20 mmol/L Hepes, pH 7.4,
1 mmol/L benzamidine, 1 mmol/L phenylmethylsulpho-
nyl fluoride, 0.2 lg of DNase, and 0.2 lg of RNase] by
freeze/thawing for three cycles. Lysates were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (7.5%) and electrophoretically transferred to nitrocel-
lulose paper. Filters were then probed with a rabbit poly-
clonal anti-P2X7 antibody raised against the synthetic
peptide corresponding to the last 20 amino acids of P2X7
protein (Alomone, Israel), used at a 1:100 dilution in Tris-
buffered saline, followed by a goat antirabbit IgG anti-
body conjugated to alkaline phosphatase. Immunocom-
plexes were revealed by autoradiography and quantified
by scanning densitometry. Results were normalized to the
signal of connexin 43, as revealed by the use of a rabbit
polyclonal antibody (Sigma Chemical Co.) at 1:5000 dilu-
tion. The expression of this cytoskeleton and gap junction
protein was preliminary shown to be unaffected by high
glucose.
Functional activity of these receptors was confirmed
by assessing intracellular calcium mobilization in re-
sponse to 1 mmol/L ATP. Changes in intracellular calcium
concentration ([Ca2+]i) were measured in rat mesan-
gial cells monolayers using Fura-2/AM, as previously
reported [23]. Experiments were performed in a Perkin-
Elmer LS50 fluorimeter (Perkin-Elmer, Beaconsfield,
UK) equipped with a thermostat-controlled (37◦C) cu-
vette holder and magnetic stirring. In addition, functional
activity of P2X7 despite low level expression was verified
by immunofluorescence analysis of pore formation by
this receptor [24]. Briefly, cells seeded on glass coverslips
were rinsed with phosphate-buffered saline (PBS) and
fixed with 2% paraformaldehyde in PBS. Then, fixed cells
were permeabilized with 0.1% Triton X-100 in PBS for
30 minutes, incubated with 2% fetal calf serum in PBS
for 20 minutes, rinsed, and incubated overnight at 4◦C
with the rabbit anti-P2X7 polyclonal antibody at 1:50 di-
lution. The next day, cells were incubated for 30 min-
utes with a fluorescein isothyocianate-conjugated goat
antirabbit IgG, diluted 1:200, rinsed, and analyzed with
a TE-300 Nikon (Nikon Co., Tokyo, Japan) fluorescence
microscope.
Levels of ATP and activity of ecto-ATPases
ATP levels were measured by luminometric assay [25],
using the ATP-Lite Luminescence ATP Detection As-
say System (Perkin-Elmer, Boston, MA, USA), that has
the advantages over other systems of higher sensitivity
(down to five cells in 100 lL medium) and reproducibil-
ity, longer half-life of the light emission (>5 hours) and,
particularly, more efficient inactivation of ectoenzymes
(by raising the pH of the cell culture medium through the
addition of the mammalian cell lysis solution), thus avoid-
ing underestimation of eATP concentration. Briefly, rat
mesangial cells were seeded at a concentration of 5 × 104
cells/well in microtiter plastic dishes in a total volume of
culture medium of 100 lL, rinsed and supplemented with
the substrate solution (luciferase + D-luciferin). Then,
cells were placed directly into the test chamber of a lu-
minometer (Victor 3) (Perkin-Elmer) and light emission
was recorded in order to obtain eATP levels. Finally, cells
were treated with a lysis solution, shaken for 5 minutes,
and measurement was repeated to determine total ATP
levels; intracellular ATP was calculated by subtraction.
The activity of ecto-ATPases was measured spec-
trophotometrically in the presence of 1 mmol/L ATP,
as described by Ames [26]. Briefly, ∼3 × 105 cells were
placed in 24-well plates, washed with phosphate-free
saline solution, and incubated with 1 mmol/L ATP at 37◦C
for 15 minutes (for these cells, the ecto-ATPase activity
is maximum after this time of incubation). The medium
was then collected, centrifuged at 1100 × g for 10 min
and 300 lL of supernatant were challenged with 700 lL
of reagent (one part of 10% ascorbic acid and six parts of
0.42% ammonium molybdate in 1 N K2SO4) at 37◦C for
1 hour. Finally, phosphate released by this reaction was
quantified by recording absorbance at 820 nm. Sensitivity
of this method was 0.1 to 0.5 lmol/L inorganic phosphate.
ECM and TGF-b production
Transcripts for the ECM components fibronectin,
laminin B1, and collagen IV a1 chain and the prosclerotic
cytokine TGF-b1 were assessed by competitive RT-PCR
[27]. Briefly, 1 lg of total RNA, extracted as previously
described, was reverse transcribed using Retroscript Kit
(Ambion, Austin, TX, USA). The following primers were
used: fibronectin sense 5′-AGC GGT GTG GTC TAC
TCT GT-3′ and antisense 5′-GAT GCA CTG ATC TCG
GAF CT-3′; laminin B1 sense 5′-TGT CAG TCA CCT
GCA GGA TG-3′ and antisense 5′-CAG GAT CCA
GCA CAC GAT AG-3′; collagen IV a1 chain sense 5′-
TCG GCT ATT CCT TCG TGA TG-3′ and antisense
5′-TCT CGC TTC TCT CTA TGG TG-3′; TGF-b1 sense
5′-ATA CAG GGC TTT CGC TTC AG-3′ and antisense
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Fig. 1. P2YR and P2XR expression in rat
mesangial cells grown under normal glu-
cose (NG) and high glucose (HG) condi-
tions for 10 to 15 days. (A) Gene expres-
sion of P2YRs, P2XRs and housekeeping b-
actin (b-ac). Representative agarose gels of
polymerase chain reaction products from two
different cell lines and DNA markers. (B)
Protein expression of P2XR7 and reference
protein connexin 43 (Cx43) (representative
Western blot). (C) P2XR7 protein expression,
distribution, and pore formation (representa-
tive immunofluorescence images at low and
high magnification, upper and bottom, respec-
tively).
5′-GTC CAG GCT CCA AAT GTA GG-3′; and b-actin
sense 5′-TCT AGG CAC CAA GGT GTG-3′ and anti-
sense 5′-TCA TGA GGT AGT CCG TCA GG-3′. The
mutants were made by creating a deletion in the origi-
nal PCR product and preliminary experiments were per-
formed to establish the range of mutant concentrations
producing a slope of the line close to one and within which
the equivalence point falls (approximately in the middle).
After electrophoresis of PCR products, the ratio of un-
known cDNA/mutant was quantified by scanning densit-
ometry using the ImageJ software, a public domain Java
image processing program inspired by NIH Image, and
results were expressed as the ratio of each target to b-
actin mRNA level.
Fibronectin content of monolayers extracted with 0.5 N
NaOH and the amounts of fibronectin and TGF-b1
released in the medium during the 8 hours following incu-
bation with purinergic agonists or antagonists were mea-
sured by enzyme-linked immunosorbent assay (ELISA),
as previously reported [28]. The levels of fibronectin in
cell extracts and conditioned media, were quantified us-
ing a rabbit polyclonal antibody against rat fibronectin
(Calbiochem, San Diego, CA, USA), whereas release of
TGF-b1 was measured using the Quantikine TGF-b1 Kit
(R&D Systems), preceded by activation of TGF-b1 by
acidification. To assess bioactive TGF-b1 levels, measure-
ments were performed also without prior acidification
using 20-fold concentrated media, obtained by lyophyl-
ization. Values were normalized to the DNA content of
monolayers, as assessed fluorimetrically in 0.5 N NaOH
extracts after reaction with 0.6 lmol/L 4,6-diamidino-2-
phenylindole (Sigma Chemical Co.), as previously de-
scribed [28].
Statistical analysis
Values were expressed as mean ± SD; the percent
change was also calculated. Statistical significance was
evaluated by one-way analysis of variance (ANOVA) fol-
lowed by the Student-Newman-Keuls test for multiple
comparisons. All statistical tests were performed on raw
data.
RESULTS
Expression and functional activity of purinergic receptors
We first investigated P2R expression by RT-PCR. The
following subtypes were found to be expressed: P2Y1,
P2Y2, P2Y4, P2Y6, P2X2, P2X3, P2X4, P2X5, and P2X7.
Quantification of ethidium bromide bands at scanning
densitometry did not show significant differences in P2Y
or P2X expression in cells grown in high glucose vs. nor-
mal glucose and, therefore, we did not move on to com-
petitive RT-PCR. Among P2XRs, P2X2, P2X3, and P2X7
were weakly expressed, while P2X4 and P2X5 showed a
strong band (Fig. 1A). As it has been previously reported
that P2X7 is present (though weakly expressed) and func-
tional in rat mesangial cells [13, 18], we further assessed
its expression by Western blot analysis. This confirmed
P2X7 expression, albeit at a rather low level and also
showed a strong band of approximately 65 kD (Fig. 1B),
as previously reported by us in fibroblasts [23] and other
investigators in brain [29]. This band has been referred
to as the nonglycosylated form of P2X7 [29], though it
was observed also in microglial cells from P2X7 knock-
out mice [30].
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Table 1. Adenosine triphosphate (ATP) levels and ecto-ATPase
activity in rat mesangial cells grown under normal glucose vs. high
glucose conditions (mean ± SD)
Normal glucose High glucose
ATP
Extracellular lmol/L 0.52 ± 0.13 (N = 6) 1.08 ± 0.17 (N = 6)a
Intracellular lmol/L 1650 ± 440 (N = 6) 1460 ± 710 (N = 6)
EctoATPase activity nmol 29.4 ± 7.8 (N = 7) 31.0 ± 5.1 (N = 7)
inorganic phosphorus/
hour/3 × 105 cells
aSignificantly different vs. normal glucose (P < 0.001).
To confirm that P2Rs detected in rat mesangial cells
were functionally active, we next assessed [Ca2+]i in re-
sponse to 1 mmol/L ATP. ATP stimulation produced an
increase in [Ca2+]i that did not differ between normal
glucose and high glucose conditions (+115 ± 19 nmol/L
vs. + 120 ± 28 nmol/L over baseline values). However,
at variance with previous studies with human fibroblasts
[31], basal [Ca2+]i was slightly but significantly higher in
rat mesangial cells cultured in high glucose vs. those in
normal glucose (121 ± 10 nmol/L vs. 80 ± 16 nmol/L)
(P < 0.05). Immunofluorescence analysis with anti-P2X7
antibody showed ring-like membrane structures mainly
localized at the periphery of the cell, clearly indicating
pore formation, with no difference under high glucose
vs. normal glucose conditions (Fig. 1C), thus ruling out
the possibility that high glucose could have increased the
recruitment of P2X7 onto the plasma membrane.
Levels of eATP and ecto-ATPase activity
We previously reported that fibroblasts from type 2
diabetic patients release a higher amount of ATP into
the pericellular space [31]. This suggested that either an
inborn defect or the chronic exposure to hyperglycemia
might be responsible for a higher spontaneous ATP se-
cretion. Thus, we checked the effect of high glucose on
the amount of ATP released by rat mesangial cells. Cells
grown in high glucose secreted almost twice as much ATP
as those in normal glucose, whereas total intracellular
ATP levels were unchanged (Table 1). Iso-osmolar man-
nitol did not mimic the effect of high glucose on ATP
secretion (0.49 ± 0.13 lmol/L), thus indicating that the
increased ATP release under high glucose conditions was
not dependent on enhanced cell death. This was sup-
ported also by the observation that both high glucose
and iso-osmolar mannitol did not affect cell viability, as
assessed by lactate dehyrogenase (LDH) release (15 ±
7 and 14 ± 7, respectively vs. 14 ± 5% in normal glu-
cose) and tripan blue exclusion (not shown). Another
possible explanation for the higher eATP level in high
glucose might be a lower ecto-ATPase activity. However,
measurement of inorganic phosphate accumulation un-
0
0.5
1.0
1.5
NG HG
* ‡ *‡
A
0
0.5
1.0
1.5
NG HG
* ‡ *‡
C
0
0.5
1.0
1.5
NG HG
* ‡ †‡
B
0
0.5
1.0
1.5
NG HG
* ‡ †‡
D
Fig. 2. mRNA levels of fibronectin (A), laminin B1 (B), collagen IV a1
chain (C), and transforming growth factor-b1 (D) (expressed as optical
density ratio to b-actin mRNA level) in rat mesangial cells incubated
with nucleotide scavengers. The cells were grown under normal glucose
(NG) and high glucose (HG) conditions for 10 to 15 days, then left
untreated () or incubated for 4 hours with hexokinase (50 lg/mL)
() or apyrase (0.4 U/mL) ( ). Mean ± SD (N = 6 per experimental
conditions). Significantly different vs. normal glucose at ∗P < 0.001 or
†P < 0.01; and vs. high glucose at ‡P < 0.001.
der these conditions suggested that this was not the case
(Table 1).
ECM and TGF-b production
It is known that high glucose stimulates production of
ECM proteins and TGF-b from rat mesangial cells [20].
Our study confirmed this fibrogenic effect of high glu-
cose, that was not mimicked by iso-osmolar mannitol (not
shown), thus ruling out a role for osmolarity, as previously
reported [28].
In this work, we tested the hypothesis that eATP is in-
volved in this response by assessing the effect of removal
of eATP by addition of hexokinase or apyrase, two potent
nucleotide scavengers. Treatment with these scavengers
did not produce significant effects in rat mesangial cells
grown in normal glucose, whereas it reduced substantially
(by 60% to 70%) the gene expression of matrix proteins
and TGF-b in rat mesangial cells grown in high glucose
(Fig. 2), thus suggesting that the increased ATP release
induced by high glucose may participate in the process of
ECM accumulation.
The addition of increasing doses of exogenous ATP
under normal glucose conditions produced a dose-
dependent increase of fibronectin, laminin, collagen IV,
and TGF-b1 mRNA levels, thus confirming that an ex-
cess of ATP stimulates matrix production. The same
phenomenon was observed in high glucose, though the
percent increase was lower than in normal glucose, due
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Fig. 3. mRNA levels of fibronectin (A), laminin B1 (B), collagen IV a1
chain (C), and transforming growth factor-b1 (D) (expressed as optical
density ratio to b-actin mRNA level) in rat mesangial cells incubated
with adenosine triphosphate. The cells were grown under normal glu-
cose (NG) and high glucose (HG) conditions for 10 to 15 days, then left
untreated () or incubated for 4 hours with increasing doses of adeno-
sine triphosphate 0.05 mmol/L ( ), 0.10 mmol/L ( ), and 0.30 mmol/L
(). Mean ± SD (N = 6 per experimental conditions). Significantly dif-
ferent vs. normal glucose at ∗P < 0.001 or †P < 0.01; and vs. high glucose
at ‡P < 0.001, §P < 0.01, or ‖P < 0.05.
to the marked stimulation of matrix production induced
by high glucose per se (Fig. 3). The lower effective dose
was 0.01 mmol/L (though increases were not significant
for some of the targets examined) and no further increase
was observed with doses >0.30 mmol/L (not shown).
Several ATP effects are mimicked by the analogue Bz-
ATP, a strong and selective P2X4 and P2X7 agonist [32].
Figure 4 shows that this compound was a quite as potent
agonist as ATP. As rat mesangial cells also express P2Y2
and P2Y4 that are strongly activated by UTP [33], we also
tested the effect of UTP on matrix and TGF-b produc-
tion. Figure 5 shows that, contrary to ATP and Bz-ATP,
UTP caused a marked inhibition of fibronectin, laminin,
collagen IV, and TGF-b1 mRNA expression, both under
normal glucose and high glucose conditions. The potent
P2Y1 agonist 2-MeS-ATP [34] had no effect on matrix or
TGF-b gene expression (not shown).
A potent, albeit not very selective, P2X antagonist
is the Schiff base-forming compound oATP [35]. While
oATP may also block non-P2Rs [36], it is useful in dis-
criminating between P2XRs and P2YRs because P2YRs
are not inhibited at oATP concentrations that completely
wipe out any P2X activity [35]. Figure 6 shows that, un-
der normal glucose, oATP had no effect on basal ECM
and TGF-b gene expression, but reduced significantly (by
60%) that stimulated by ATP. Under high glucose, a con-
dition that per se causes ECM and TGF-b up-regulation,
oATP also reduced basal transcript level, though to a
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Fig. 4. mRNA levels of fibronectin (A), laminin B1 (B), collagen IV a1
chain (C), and transforming growth factor-b1 (D) (expressed as optical
density ratio to b-actin mRNA level) in rat mesangial cells incubated
with benzoyl-benzoyl adenosine triphosphate (Bz-ATP). The cells were
grown under normal glucose (NG) and high glucose (HG) conditions
for 10 to 15 days, then left untreated () or incubated for 4 hours with in-
creasing doses of benzoyl-benzoyl adenosine triphosphate 0.05 mmol/L
( ), 0.10 mmol/L ( ), and 0.30 mmol/L (). Mean ± SD (N = 6 per
experimental conditions). Significantly different vs. normal glucose at
∗P < 0.001, †P < 0.01, or ‡P < 0.05; and vs. high glucose at §P < 0.001
or ‖P < 0.01.
0
0.5
1.0
1.5
NG HG
* *
*
* *‡*‡
A
†
0
0.5
1.0
1.5
NG HG
*
*
* *§
*‡*‡
B
0
0.5
1.0
1.5
NG HG
*
*
*
* *§ †‡*‡
D
0
0.5
1.0
1.5
NG HG
*
†
*
*
*§
*‡*‡
C
Fig. 5. mRNA levels of fibronectin (A), laminin B1 (B), collagen IV a1
chain (C), and transforming growth factor-b1 (D) (expressed as optical
density ratio to b-actin mRNA level) in rat mesangial cells incubated
with uridine triphosphate. The cells were grown under normal glucose
(NG) and high glucose (HG) conditions for 10 to 15 days, then left
untreated () or incubated for 4 hours with increasing doses of uridine
triphosphate 0.05 mmol/L ( ), 0.10 mmol/L ( ) and 0.30 mmol/L ().
Mean ± SD (N = 6 per experimental conditions). Significantly different
vs. normal glucose at ∗P < 0.001 or †P < 0.01; and vs. high glucose at
‡P < 0.001 or §P < 0.05.
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Fig. 6. mRNA levels of fibronectin (A), laminin B1 (B), collagen IV
a1 chain (C), and transforming growth factor-b1 (D) (expressed as op-
tical density ratio to b-actin mRNA level) in rat mesangial cells in-
cubated with oxidized ATP. The cells were grown under normal glu-
cose (NG) and high glucose (HG) conditions for 10 to 15 days, then
left untreated () or incubated for 4 hours with 0.30 mmol/L adeno-
sine triphosphate (ATP) ( ), for 2 hours with 0.30 mmol/L oxidized
ATP ( ), or for 2 hours with 0.30 mmol/L oxidized ATP followed
by 4-hour coincubation with 0.30 mmol/L ATP (). Mean ± SD (N
= 6 per experimental conditions). Significantly different vs. normal
glucose at ∗P < 0.001 or †P < 0.05; vs. high glucose at ‡P < 0.01 or
§P < 0.05; and vs. ATP at ‖P < 0.001.
lesser extent (by 40%). We also tested two additional in-
hibitors, the wide spectrum P2R antagonist PPADS [37]
and the selective P2Y1 blocker MRS-2179 [37], but nei-
ther of them affected significantly ECM or TGF-b gene
expression (not shown).
The use of a TGF-b blocking antibody, but not
nonimmune IgG, virtually prevented ATP-induced up-
regulation of fibronectin, laminin, and collagen IV gene
expression under normal glucose conditions (Fig. 7), thus
suggesting a TGF-b–dependent mechanism for puriner-
gic modulation of ECM production.
Cell and medium content of fibronectin (Table 2) and
total TGF-b1 released from cells (Table 3) showed the
same trend of mRNA expression. Bioactive TGF-b1 in
conditioned media was also increased by high glucose
(28.1 ± 2.9), 0.30 mmol/L ATP (24.7 ± 3.5) and Bz-ATP
(25.3 ± 3.2) and reduced by 0.30 mmol/L UTP (12.9 ± 3.0)
vs. normal glucose (17.1 ± 2.2 pg/lg DNA) (P < 0.001);
moreover, hexokinase reduced significantly (P < 0.001)
high glucose–induced up-regulation of bioactive TGF-b1
(22.7 ± 3.3).
DISCUSSION
The present paper reports on the effect of eATP on
ECM and TGF-b production in rat mesangial cells grown
0
0.2
0.4
0.6
0.8
1.0
1.2 A * *
†
0
0.2
0.4
0.6
0.8
1.0
1.2
B
* *
†
0
0.2
0.4
0.6
0.8
1.0
1.2
C
* *
†
Fig. 7. mRNA levels of fibronectin (A), laminin B1 (B), and collagen
IV a1 chain (C) (expressed as optical density ratio to b-actin mRNA
level) in rat mesangial cells incubated with transforming growth factor
b (TGF-b) neutralizing antibody. The cells were grown under normal
glucose conditions for 10 to 15 days, then left untreated () or incubated
for 4 hours with 0.30 mmol/L adenosine triphosphate (ATP) alone ( ),
0.30 mmol/L ATP plus 30 lg/mL nonimmune IgG ( ), or 0.30 mmol/L
ATP plus 30 lg/mL TGF-b neutralizing antibody (). Mean±SD (N =6
per experimental conditions). Significantly different vs. normal glucose
at ∗P < 0.001; and vs. ATP at †P < 0.001.
under normal glucose and high glucose conditions. Taken
together, our observations show that eATP might be in-
volved in the pathogenesis of ECM accumulation and
consequent mesangial expansion occurring in diabetic
and other glomerular diseases.
The levels that eATP may reach in the extracellular
space are a matter of debate and estimates range from
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Table 2. Cell and medium fibronectin levels (lg/lg DNA) (mean ± SD) (N = 6 per experimental conditions) in rat mesangial cells grown under
normal glucose vs. high glucose conditions ± various purinergic agonists or antagonists and nonimmune IgG or transforming growth factor-b
(TGF-b) blocking antibody
Cell Medium
Normal glucose High glucose Normal glucose High glucose
Untreated 2.081 ± 0.183 3.264 ± 0.322a 0.821 ± 0.074 1.344 ± 0.136a
+ hexokinase (50 lg/mL) 2.204 ± 0.357 2.749 ± 0.240a,e 0.867 ± 0.054 1.117 ± 0.142a,d
+ apyrase (4 U/mL) 2.159 ± 0.222 2.842 ± 0.397a,e 0.841 ± 0.091 1.167 ± 0.155a,e
Untreated 2.223 ± 0.161 3.183 ± 0.244a 0.954 ± 0.088 1.407 ± 0.155a
+ ATP (0.05 mmol/L) 2.422 ± 0.145 3.343 ± 0.136a 1.031 ± 0.066 1.501 ± 0.133a
+ ATP (0.10 mmol/L) 2.640 ± 0.155a 3.465 ± 0.154a,e 1.159 ± 0.078b 1.624 ± 0.154a,d
+ ATP (0.30 mmol/L) 2.964 ± 0.178a 3.664 ± 0.211a,d 1.277 ± 0.090a 1.728 ± 0.159a,d
Untreated 2.121 ± 0.123 3.082 ± 0.277a 0.911 ± 0.066 1.355 ± 0.143a
+ Bz-ATP (0.05 mmol/L) 2.324 ± 0.158 3.380 ± 0.367a 1.011 ± 0.076 1.467 ± 0.124a
+ Bz-ATP (0.10 mmol/L) 2.596 ± 0.178a 3.524 ± 0.344a,e 1.150 ± 0.070a 1.600 ± 0.144a,d
+ Bz-ATP (0.30 mmol/L) 2.786 ± 0.223a 3.764 ± 0.256a,d 1.249 ± 0.101a 1.689 ± 0.107a,d
Untreated 2.220 ± 0.118 3.101 ± 0.234a 0.976 ± 0.079 1.376 ± 0.124a
+ UTP (0.05 mmol/L) 2.021 ± 0.157 2.840 ± 0.289a 0.904 ± 0.080 1.294 ± 0.155a
+ UTP (0.10 mmol/L) 1.859 ± 0.178b 2.702 ± 0.345a,d 0.825 ± 0.056 1.229 ± 0.133a
+ UTP (0.30 mmol/L) 1.678 ± 0.218a 2.524 ± 0.265a,d 0.759 ± 0.082a 1.158 ± 0.124a,d
Untreated 2.111 ± 0.141 3.063 ± 0.261a 0.916 ± 0.059 1.287 ± 0.133a
+ ATP (0.30 mmol/L) 2.728 ± 0.201a NA 1.211 ± 0.072a NA
+ oATP (0.30 mol/L) 2.181 ± 0.217 2.745 ± 0.314a,e 0.967 ± 0.086 1.128 ± 0.078a,e
+ oATP + ATP (0.30 mmol/L) 2.433 ± 0.115c,g NA 1.089 ± 0.056a,g NA
Untreated 2.187 ± 0.154 NA 0.915 ± 0.067 NA
+ ATP (0.30 mmol/L) 3.067 ± 0.232a NA 1.314 ± 0.087a NA
+ ATP + IgG (30 lg/mL) 3.101 ± 0.172a NA 1.297 ± 0.088a NA
+ ATP + a-TGF-b (30 lg/mL) 2.381 ± 0.187f NA 1.001 ± 0.043f NA
Abbreviations are: ATP, adenosine triphosphate; Bz-ATP, benzoylbenzoylATP; oATP, oxidized ATP; a-TGF-b , TGF-b blocking antibody; NA, not assessed; UTP,
uridine triphosphate.
Significantly different vs. normal glucose at aP < 0.001, bP < 0.01 or cP < 0.05; vs. high glucose at dP < 0.001 or eP < 0.01; and vs. ATP at fP < 0.001 or gP < 0.05.
the high micromolar to the nanomolar range [1], depend-
ing on the tissue/cell type examined and, particularly, the
efficacy of ectoenzyme inactivation in the assay pro-
cedure. An accurate quantitation of eATP concentra-
tions is further compounded by the likely occurrence
of ATP secretion in protected intercellular compart-
ments (e.g., at sites of close cell-to-cell interactions, see
below) [39]. Some environmental conditions such as
hypoxia/ischemia, stress injury, or membrane damage
can induce a release of ATP in the extracellular space
from several sources: platelets, endothelial cells, vascular
smooth muscle cells, and inflammatory cells [1]. While it
is already known that nondamaged cells may release ATP
under experimental inflammatory conditions [40], this is
the first report, to our knowledge, of an increased eATP
release from cells under high glucose conditions (and the
same phenomenon might occur at the level of other res-
ident and nonresident glomerular cells). Several mecha-
nisms are likely to mediate nonlytic ATP release, though
none of them has been so far shown to be ubiquitous.
These mechanisms include nonvesicular efflux pathways
involving connexins or connexin-related proteins (pan-
nexins), ATP-binding cassette proteins, stretch-activated
channels, and the plasmalemmal voltage-dependent an-
ion channel, and vesicular trafficking, due to stimulated or
constitutive exocytosis, particularly in nonexcitable cells
[41]. Accordingly, several intracellular second messen-
ger systems have been shown to modulate ATP release,
including elevation of [Ca2+]i and activation of phos-
phoinositide 3-kinase and Rho kinase [42]. Thus, we can
speculate that high glucose may promote ATP release by
activating one or more of these signaling pathways, as
previously shown in mesangial and other vascular cells
[43–45]. In addition, oxidative stress, which is known
to be induced by high glucose, might mediate glucose-
stimulated ATP release, as suggested by the demonstra-
tion that hyperoxia enhances eATP levels by promoting
the generation of reactive oxygen species in endothelial
cells [46]. This enhanced ATP release occurred in the ab-
sence of changes in the expression and function of P2Rs,
thus suggesting an activation of the purinergic system
mainly driven by increased nucleotide level rather than
by change of P2R number or activity. Activation of the
purinergic loop seems to be mainly required for ECM and
TGF-b production in high glucose, since incubation with
ATP-hydrolyzing enzymes was without effect under nor-
mal glucose conditions. This is not surprising, since even
the use of a blocking antibody against TGF-b1, the major
cytokine involved in the up-regulation of ECM produc-
tion in response to high glucose or hyperglycemia, has
little effect on this parameter both in vitro under nor-
mal glucose [47] and in vivo in normoglycemic condi-
tions [48]. Activation of rat mesangial cells responses by
exogenous ATP required doses in the medium-high mi-
cromolar range, similar to the threshold for purinergic re-
ceptor activation noted in other studies using mesangial
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Table 3. Medium transforming growth factor-b (TGF-b1) levels
(ng/lg DNA) (mean ± SD) (N = 6 per experimental conditions) in rat
mesangial cells grown under normal glucose vs. high glucose
conditions ± various purinergic agonists or antagonists
Normal glucose High glucose
Untreated 0.74 ± 0.09 1.05 ± 0.12a
+ hexokinase (50 lg/mL) 0.72 ± 0.07 0.87 ± 0.12e
+ apyrase (4 U/mL) 0.78 ± 0.06 0.90 ± 0.14c,e
Untreated 0.71 ± 0.08 1.02 ± 0.09a
+ ATP (0.05 mmol/L) 0.79 ± 0.04 1.09 ± 0.12a
+ ATP (0.10 mmol/L) 0.82 ± 0.05 1.15 ± 0.08a,e
+ ATP (0.30 mmol/L) 0.91 ± 0.07a 1.23 ± 0.10a,d
Untreated 0.76 ± 0.07 1.04 ± 0.10a
+ Bz-ATP (0.05 mmol/L) 0.86 ± 0.09 1.10 ± 0.08a
+ Bz-ATP (0.10 mmol/L) 0.90 ± 0.06c 1.16 ± 0.12a,e
+ Bz-ATP (0.30 mmol/L) 0.99 ± 0.08a 1.27 ± 0.14a,d
Untreated 0.72 ± 0.07 1.03 ± 0.12a
+ UTP 0.05 (mmol/L) 0.65 ± 0.06 0.97 ± 0.11a
+ UTP (0.10 mmol/L) 0.59 ± 0.08 0.90 ± 0.10a
+ UTP (0.30 mmol/L) 0.54 ± 0.07b 0.86 ± 0.14b,e
Untreated 0.75 ± 0.06a 1.03 ± 0.13a
+ ATP (0.30 mmol/L) 0.96 ± 0.08 NA
+ oATP (0.30 mmol/L) 0.74 ± 0.07 0.90 ± 0.07a,e
+ oATP + ATP (0.30 mmol/L) 0.84 ± 0.04f NA
Abbreviations are: ATP, adenosine triphosphate; Bz-ATP, benzoylbenzoy-
lATP; oATP, oxidized ATP; UTP, uridine triphosphate; NA, not assessed.
Significantly different vs. normal glucose at aP < 0.001, bP < 0.01 or cP < 0.05;
vs. high glucose at dP < 0.001 or eP < 0.05; and vs. ATP at fP < 0.05.
and other glomerular cells [9, 13, 15–18] and also different
cell types [37]. Conversely, the bulk concentrations mea-
sured by the luciferase-D-luciferin assay in rat mesangial
cells grown under high glucose conditions, though almost
doubled than those in normal glucose, were still in the
low micromolar range, in keeping with previous reports
in other stimulated cell systems [1]. However, as discussed
by many other investigators and elegantly shown in re-
cent studies in activated platelets [39], local ATP concen-
trations near the cell surface, and, accordingly, near the
purinergic receptors might be much higher than those
measured in the conditioned media also in mesangial
cells, thus explaining this apparent discrepancy.
ATP is a wide range P2R agonist, since it activates sev-
eral P2Rs of both subtypes. As previously reported in rat
mesangial cells for cell proliferation and death [13–18],
P2YRs and P2XRs may exert opposite actions, the net
effect of ATP being the result of these actions. Thus, in
order to identify the specific role of each P2R subtype
and the individual receptor(s) involved in the modula-
tion of ECM production, we performed a molecular and
pharmacologic characterization.
The analysis of P2R expression confirmed and ex-
tended previous observations showing that RMC express
the several P2XRs and P2YRs [13, 14]. The P2X7 ago-
nist Bz-ATP mimicked the effect of ATP, whereas the
P2X7 irreversible inhibitor oATP partially prevented it,
thus suggesting a prosclerotic role for this receptor. The
observation that attenuation of the effect of high glu-
cose by oATP was less evident than the reduction of
ATP-induced changes might be related to the multiple
mechanisms involved in the prosclerotic effect of hyper-
glycemia, part of which are not dependent on the ac-
tivation of the purinergic system. Biochemical analysis
confirmed the expression of P2X7 at both the mRNA and
protein level, even if at low transcript level despite its rel-
evant functional activity, as previously reported by others
[13]. In addition to P2X7, whose functional role has been
partly elucidated [37], other P2XRs were also detected in
rat mesangial cells (i.e., the subtypes P2X2, P2X3, P2X4
and P2X5). Though their function is still unclear, one of
them, P2X4, shares some properties with P2X7, in partic-
ular the ability to form nonselective plasma membrane
pores [49].
At variance with Bz-ATP, UTP, an uracil nucleotide,
which is the preferred agonist at P2Y2 and P2Y4 and an
effective stimulus for P2Y6 [33], strongly reduced ECM
and TGF-b mRNA and protein expression in a dose-
dependent fashion, thus indicating that P2YRs exert an
opposite effect on matrix production.
The prevention of ECM up-regulation by the use of a
TGF-b blocking antibody indicates that purinergic mod-
ulation of ECM production is TGF-b–dependent and
suggests that, under high glucose conditions, glucose and
ATP may act in a synergistic or additive manner to stimu-
late TGF-b production. This is supported by the demon-
stration that both high glucose [50] and eATP [16] are
capable of activating the MAPK cascade.
Desensitization of P2YRs has been demonstrated in
different cell lines and preparations [51]. Both under high
glucose conditions and upon addition of exogenous ATP,
the pro-sclerotic activity of P2XRs seems to prevail over
that of P2YRs, which might be in a state of chronic de-
sensitization, as already shown in other cell types under
the same experimental conditions [52]. However, this is
in contrast with the report that similar doses of ATP pro-
duced a stimulation of rat mesangial cell proliferation
that was mimicked by equimolar UTP, whereas Bz-ATP
produced the opposite effect, thus indicating that, under
those circumstances, exogenous ATP acted primarily via
P2YRs [13]. The fact that 2-MeS-ATP, a specific P2Y1
agonist, did not produce any significant effect might be
explained by the minor role played by P2Y1, as further
confirmed by the lack of effect of the selective P2Y1 an-
tagonist MRS-2179.
Taken together, our results, together with previously
reported data [13–18], have several important implica-
tions in the pathogenesis of diabetic and other glomeru-
lar diseases. In fact, both cell and matrix turnover were
shown to be modulated by the purinergic system at the
glomerular/mesangial level. Thus, the main, strictly re-
lated processes that underlie both maintenance of nor-
mal tissue homeostasis and development of glomerular
diseases [53] would be influenced by eATP levels, which
in turn might be affected by either chronic hyperglycemia
or acute inflammation with increased ATP release from
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platelets and other cells (and possibly up-regulation of
P2XR7 [14]). The resulting effect would be dependent
on the prevalence of the effect of P2XRs, with conse-
quent apoptosis and matrix deposition, or P2YRs, lead-
ing to proliferation and inhibition of ECM accumulation.
Mechanisms regulating this balance are as yet unclear and
deserve further investigation. In particular, elucidation of
P2YR desensitization and resensitization would be ex-
tremely important for the understanding of the physio-
logic role of extracellular nucleotides and their possible
therapeutic use in glomerular diseases.
Among the various biochemical mechanisms impli-
cated in the injurious effect of hyperglycemia, PKC acti-
vation seems to play a major role [54]. Recent evidence
suggests a link between PKC and the purinergic system.
In fact, PKC activation was shown to induce desensitiza-
tion of P2Y2 in rat mesangial cells [55], that is in keeping
with our finding of a down-regulatory effect of P2YRs on
mesangial matrix production. Moreover, stimulation of
rat mesangial cells with ATP and UTP leads to a rapid
activation of the PKB pathway, a cascade known to play
an important role in the antiapoptotic, but not inflamma-
tory or mitogenic response [56].
CONCLUSION
The purinergic system appears to be involved in the
modulation of ECM production in rat mesangial cells,
with eATP exerting a dual effect: a stimulatory, probably
via P2X7, and an inhibitory, via a P2YR. In the presence
of elevated eATP levels, due to increased release from
mesangial (and other glomerular or nonresident) cells,
as in response to high glucose concentrations (and possi-
bly ischemic or inflammatory conditions), ECM proteins
accumulate as a result of a functional predominance of
P2XRs (electively stimulated by higher ATP concentra-
tions) over P2YRs. This mechanism might participate in
the pathogenesis of mesangial expansion occurring in di-
abetic and possibly any other glomerular disease associ-
ated with increased ATP release from resident or non-
resident glomerular cells.
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